Header Logo

Connection

FILIP JANKU to Precision Medicine

Back to Details
This is a "connection" page, showing publications FILIP JANKU has written about Precision Medicine.
FILIP JANKU
Connection Strength
0.824
Precision Medicine
  1. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145.
    View in: PubMed
    Score: 0.105
  2. Moving Precision Oncology Forward Amid Myths and Misconceptions. JAMA Oncol. 2018 12 01; 4(12):1788-1789.
    View in: PubMed
    Score: 0.097
  3. Circulating tumor DNA-From bench to bedside. Curr Probl Cancer. 2017 May - Jun; 41(3):212-221.
    View in: PubMed
    Score: 0.086
  4. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn. 2015; 15(12):1631-44.
    View in: PubMed
    Score: 0.079
  5. Cell-free DNA as a novel marker in cancer therapy. Biomark Med. 2015; 9(7):703-12.
    View in: PubMed
    Score: 0.074
  6. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36.
    View in: PubMed
    Score: 0.072
  7. Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol. 2013 Aug; 24(8):2158-65.
    View in: PubMed
    Score: 0.066
  8. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
    View in: PubMed
    Score: 0.064
  9. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83.
    View in: PubMed
    Score: 0.063
  10. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST). Ann Oncol. 2024 Mar; 35(3):267-275.
    View in: PubMed
    Score: 0.034
  11. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
    View in: PubMed
    Score: 0.023
  12. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
    View in: PubMed
    Score: 0.022
  13. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701.
    View in: PubMed
    Score: 0.020
  14. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.